title: Maternal asthma, its control and severity in pregnancy, and the incidence of atopic dermatitis and allergic rhinitis in the offspring.
abstract: OBJECTIVE
  To evaluate the relationship between maternal asthma, its level of control and severity during pregnancy, and atopic dermatitis (AD) and allergic rhinitis (AR) incidence in children.
  
  
  METHODS
  A cohort of 26 265 singletons born to mothers with and without asthma (1990-2002) was constituted by use of 3 Quebec databases. Mothers with asthma had to have received >or=1 diagnosis and >or=1 prescription for asthma 2 years before or during pregnancy. Asthma control and severity during pregnancy was based on validated indexes. ICD-9 codes 691 and 477 allowed us to identify cases of AD and AR.
  
  
  RESULTS
  Maternal asthma during pregnancy was associated with an increased AD risk (adjusted hazard ratio: 1.11, 95% confidence interval: 1.02-1.21), but not of AR (adjusted hazard ratio: 1.04, 95% confidence interval: 0.91-1.20) in children. Asthma control and severity were not associated with either outcome. Maternal AR and intranasal corticosteroid use during pregnancy increased the risk of childhood AR by 70% and 45%.
  
  
  CONCLUSIONS
  Children of mothers with asthma or AR during pregnancy should be closely monitored to diagnose and treat AD and AR as early as possible.
authors.affiliation: Faculty of Pharmacy, Université de Montréal, Montréal, Québec, Canada.
authors.forename: Marie-Josée
authors.initials: MJ
authors.lastname: Martel
authors.forename: Marie-France
authors.initials: MF
authors.lastname: Beauchesne
authors.forename: Jean-Luc
authors.initials: JL
authors.lastname: Malo
authors.forename: Evelyne
authors.initials: E
authors.lastname: Rey
authors.forename: Sylvie
authors.initials: S
authors.lastname: Perreault
authors.forename: Amélie
authors.initials: A
authors.lastname: Forget
authors.forename: Lucie
authors.initials: L
authors.lastname: Blais
mesh_terms: D000328:Adult; D017677:Age Distribution; D018927:Anti-Asthmatic Agents / Q000627:therapeutic use; D001249:Asthma / Q000175:diagnosis / Q000188:drug therapy / Q000276:immunology*; D015331:Cohort Studies; D016001:Confidence Intervals; D003876:Dermatitis, Atopic / Q000175:diagnosis / Q000453:epidemiology / Q000276:immunology*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015994:Incidence; D007231:Infant, Newborn; D038801:International Classification of Diseases; D008297:Male; D015999:Multivariate Analysis; D011247:Pregnancy; D011248:Pregnancy Complications / Q000175:diagnosis / Q000188:drug therapy / Q000276:immunology*; D011336:Probability; D016016:Proportional Hazards Models; D011792:Quebec / Q000453:epidemiology; D012042:Registries; D012189:Retrospective Studies; D012221:Rhinitis, Allergic, Perennial / Q000175:diagnosis / Q000453:epidemiology / Q000276:immunology*; D012720:Severity of Illness Index; D017678:Sex Distribution
chemical_list: D018927:Anti-Asthmatic Agents